Michael H. Mulroy - Net Worth and Insider Trading
Michael H. Mulroy Net Worth
The estimated net worth of Michael H. Mulroy is at least $363,719 dollars as of 2024-05-27. Michael H. Mulroy is the Director of Lineage Cell Therapeutics Inc and owns about 258,555 shares of Lineage Cell Therapeutics Inc (LCTX) stock worth over $271,483. Michael H. Mulroy is also the President and CEO of Asterias Biotherapeutics Inc and owns about 97,604 shares of Asterias Biotherapeutics Inc (AST) stock worth over $92,236. Details can be seen in Michael H. Mulroy's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Michael H. Mulroy has not made any transactions after 2022-03-24 and currently still holds the listed stock(s).
Transaction Summary of Michael H. Mulroy
Michael H. Mulroy Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Michael H. Mulroy owns 4 companies in total, including Lineage Cell Therapeutics Inc (LCTX) , AgeX Therapeutics Inc (AGE) , and Asterias Biotherapeutics Inc (AST) among others .
Click here to see the complete history of Michael H. Mulroy’s form 4 insider trades.
Insider Ownership Summary of Michael H. Mulroy
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
LCTX | Lineage Cell Therapeutics Inc | 2022-03-24 | director |
AGE | AgeX Therapeutics Inc | 2018-11-27 | director |
AST | Asterias Biotherapeutics Inc | 2019-03-01 | director & President and CEO |
2013-10-08 | director |
Michael H. Mulroy Latest Holdings Summary
Michael H. Mulroy currently owns a total of 2 stocks. Among these stocks, Michael H. Mulroy owns 258,555 shares of Lineage Cell Therapeutics Inc (LCTX) as of March 24, 2022, with a value of $271,483 and a weighting of 74.64%. Michael H. Mulroy also owns 97,604 shares of Asterias Biotherapeutics Inc (AST) as of August 27, 2018, with a value of $92,236 and a weighting of 25.36%.
Latest Holdings of Michael H. Mulroy
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
LCTX | Lineage Cell Therapeutics Inc | 2022-03-24 | 258,555 | 1.05 | 271,483 |
AST | Asterias Biotherapeutics Inc | 2018-08-27 | 97,604 | 0.95 | 92,236 |
Holding Weightings of Michael H. Mulroy
Michael H. Mulroy Form 4 Trading Tracker
According to the SEC Form 4 filings, Michael H. Mulroy has made a total of 1 transactions in Lineage Cell Therapeutics Inc (LCTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Lineage Cell Therapeutics Inc is the acquisition of 7,000 shares on March 24, 2022, which cost Michael H. Mulroy around $9,800.
According to the SEC Form 4 filings, Michael H. Mulroy has made a total of 0 transactions in Asterias Biotherapeutics Inc (AST) over the past 5 years. The most-recent trade in Asterias Biotherapeutics Inc is the acquisition of 3,141 shares on August 27, 2018, which cost Michael H. Mulroy around $4,994.
Insider Trading History of Michael H. Mulroy
- 1
Michael H. Mulroy Trading Performance
GuruFocus tracks the stock performance after each of Michael H. Mulroy's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael H. Mulroy is -17.39%. GuruFocus also compares Michael H. Mulroy's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael H. Mulroy within 3 months outperforms 2 times out of 13 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Michael H. Mulroy's insider trading performs compared to the benchmark.
Performance of Michael H. Mulroy
Michael H. Mulroy Ownership Network
Ownership Network List of Michael H. Mulroy
Ownership Network Relation of Michael H. Mulroy
Michael H. Mulroy Owned Company Details
What does Lineage Cell Therapeutics Inc do?
Who are the key executives at Lineage Cell Therapeutics Inc?
Michael H. Mulroy is the director of Lineage Cell Therapeutics Inc. Other key executives at Lineage Cell Therapeutics Inc include 10 percent owner Broadwood Partners Lp , Chief Financial Officer Jill Ann Howe , and director & President and CEO Brian M Culley .
Lineage Cell Therapeutics Inc (LCTX) Insider Trades Summary
Over the past 18 months, Michael H. Mulroy made no insider transaction in Lineage Cell Therapeutics Inc (LCTX). Other recent insider transactions involving Lineage Cell Therapeutics Inc (LCTX) include a net purchase of 6,730,770 shares made by Broadwood Partners Lp , a net purchase of 96,155 shares made by Don M Bailey , and a net purchase of 10,000 shares made by Anula Jayasuriya .
In summary, during the past 3 months, insiders sold 0 shares of Lineage Cell Therapeutics Inc (LCTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Lineage Cell Therapeutics Inc (LCTX) were sold and 6,836,925 shares were bought by its insiders, resulting in a net purchase of 6,836,925 shares.
Lineage Cell Therapeutics Inc (LCTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Lineage Cell Therapeutics Inc Insider Transactions
Michael H. Mulroy Mailing Address
Above is the net worth, insider trading, and ownership report for Michael H. Mulroy. You might contact Michael H. Mulroy via mailing address: 1300 N. Kellogg Drive, Suite D, Anaheim Ca 92807.